Brief: Vicore Pharma Holding Q4 Operating Loss Widens To SEK 81.1 Mln

Vicore Pharma Holding AB

25/02/2022 07:21

Feb 25 (Reuters) - Vicore Pharma Holding AB  VICOR.ST :
    * YEAR-END REPORT 2021
    * Q4 OPERATING LOSS WAS -81.1 MSEK (-58.8)
    * BOARD OF DIRECTORS PROPOSES TO ANNUAL GENERAL MEETING THAT
NO
DIVIDEND BE PAID FOR FINANCIAL YEAR 2021
    * OUTLOOK: MORE THAN 50 CENTERS IN 10 COUNTRIES ARE NOW
ACTIVE AND
ACCRUING PATIENTS IN ATTRACT-3, VICORE'S PHASE 3 PIVOTAL TRIAL
IN COVID-19. EVEN THOUGH RECRUITMENT RATE HAS GROWN STEADILY,
UNPREDICTABLE COVID-19 SITUATION HAS CAUSED A DELAY IN
RECRUITMENT. WE ESTIMATE THAT READ-OUT OF RESULTS FROM TRIAL
WILL MOVE INTO SECOND HALF OF 2022 AS OPPOSED TO FIRST HALF OF
2022 AS PREVIOUSLY COMMUNICATED.

Source text for Eikon:  ID:nWkr7t4vrT 
Further company coverage:  VICOR.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))